Ironwood Pharmaceuticals
Corporate brand
UnclaimedIronwood Pharmaceuticals is a United States pharmaceutical company best known for developing linaclotide, marketed as Linzess and Constella for constipation-related gastrointestinal disorders.
Last updated August 25, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Ironwood Pharmaceuticals, Inc. is a United States pharmaceutical company focused on the discovery, development, and commercialization of medicines, particularly therapies for gastrointestinal disorders. The company originated as Microbia, Inc., a biotechnology venture founded by postdoctoral researchers associated with Gerald Fink's laboratory at the Whitehead Institute. Its initial scientific concept was broader than conventional drug development: the founders sought to use advances in fungal fermentation and genetic engineering to improve the production of industrial compounds, discover new secondary metabolites, and identify targets for antifungal medicines. The company's direction changed during the early 2000s as it recruited drug-development executives and concentrated more heavily on pharmaceutical research. In 2002, John Talley joined the organization to lead antifungal discovery, working with Mark Currie and Richard Bailey, among others. Research led by Currie resulted in linaclotide, a peptide derived from an enterotoxin associated with certain strains of Escherichia coli. Rather than causing disease, the mechanism became the basis for a medicine designed to activate intestinal guanylate cyclase-C receptors and improve bowel function. Microbia raised substantial private financing while advancing linaclotide. By 2004, it had reportedly raised $99 million and was preparing for a Phase I study. The company nevertheless faced the cost and organizational complexity of pursuing industrial biotechnology, antifungal discovery, and clinical drug development simultaneously. In 2006, it separated its activities into two businesses. Microbia Precision Engineering retained the industrial biotechnology activities under Richard Bailey, while the drug-discovery company retained the Microbia name. Tate & Lyle invested in the industrial spinout and obtained a board seat. The drug-development company changed its name to Ironwood Pharmaceuticals in 2008, while the industrial business was shortened to Microbia. Ironwood completed its initial public offering in early 2010. Later that year, it sold its interest in the industrial biotechnology business to DSM, leaving the company focused on pharmaceutical research and commercialization. Linaclotide became Ironwood's defining product. The medicine was approved in the United States and Europe in 2012 for irritable bowel syndrome with constipation and chronic idiopathic constipation. It is marketed as Linzess in the United States and Mexico and as Constella in many other markets. Ironwood licensed significant commercialization rights to partners including Allergan and Astellas, allowing the product to reach markets through established pharmaceutical sales organizations. The product became a major commercial asset and established Ironwood as a gastrointestinal-focused pharmaceutical company. Ironwood has also pursued additional gastrointestinal and central-nervous-system programs. It developed recanaclotide, formerly known as IW-9179, but discontinued the program in 2016. The company also licensed and conducted research on soclenicant, also identified as BNC-210 and IW-2143, an anxiolytic program that it subsequently abandoned. These discontinued programs illustrate the selective portfolio decisions typical of a specialized biotechnology company, in which resources are concentrated on candidates with the strongest clinical and commercial prospects. In 2018, Ironwood's shares rose sharply after activist biotechnology investor Alex Denner joined the company's board. The event highlighted investor interest in the company's strategy and in the value of its commercial gastrointestinal franchise. Ironwood remains an active, publicly traded pharmaceutical company whose identity is closely associated with linaclotide, gastrointestinal disease treatment, and the transition from its original industrial-biotechnology roots into a focused drug-development business.
History
Ironwood Pharmaceuticals began as Microbia, Inc., a biotechnology company founded by postdoctoral researchers connected with Gerald Fink's laboratory at the Whitehead Institute. The original business model combined industrial biotechnology and pharmaceutical research. Its scientists worked on improving fungal fermentation, genetically engineering fungi to make existing or novel secondary metabolites, and identifying fungal targets that could support antifungal drug discovery. During the early 2000s, Microbia increasingly emphasized pharmaceutical research. In 2002, it recruited John Talley to lead antifungal discovery. Mark Currie and Richard Bailey also joined the company's senior scientific and commercial effort. Currie's group ultimately discovered linaclotide, a peptide whose design was based on an enterotoxin produced by some strains of Escherichia coli associated with traveler's diarrhea. The compound was redirected toward therapeutic use in gastrointestinal disease. Microbia raised $99 million by 2004 and was preparing linaclotide for Phase I testing. The company subsequently encountered the financial and operational pressures of advancing a drug candidate while also operating an industrial fermentation business and pursuing antifungal research. In 2006, it divided the businesses. Microbia Precision Engineering, led by Bailey, focused on industrial applications, while the drug-discovery organization retained the Microbia name. Tate & Lyle invested $7 million in the industrial spinout and received a board seat. The drug-development company renamed itself Ironwood Pharmaceuticals in 2008. The industrial company adopted the shorter Microbia name. By 2009, Ironwood had raised a reported total of $281 million. It held an initial public offering in early 2010, pricing the shares at $11.25, below the previously discussed target price of $14. Later in 2010, Ironwood sold its interests in Microbia to DSM for an undisclosed amount. This transaction completed the company's move away from its industrial-biotechnology origins. Ironwood's principal clinical and commercial achievement was linaclotide. The drug was approved in the United States and Europe in 2012 for irritable bowel syndrome with constipation and chronic idiopathic constipation. The United States and Mexican product is called Linzess, while many other markets use the name Constella. Ironwood granted important marketing rights to Allergan and Astellas, using partnerships to broaden commercialization without building every international sales operation itself. The company continued to evaluate additional candidates but narrowed its portfolio when programs did not meet its strategic or development objectives. Recanaclotide, also called IW-9179, was discontinued in 2016. Ironwood also licensed soclenicant, identified as BNC-210 and IW-2143, and conducted research on it as an anxiolytic before abandoning the program. Ironwood attracted renewed investor attention in 2018 when activist biotechnology investor Alex Denner joined its board. Its history reflects a transition from a diversified biotechnology start-up working across fermentation and drug discovery into a publicly traded specialty pharmaceutical company centered on gastrointestinal medicine. Linaclotide remains the central product associated with the Ironwood name.
- 2018
Alex Denner joins the board
[1]The appointment of activist investor Alex Denner to Ironwood's board was followed by a rise of more than 10 percent in the company's shares.
- 2016
Recanaclotide program is discontinued
[1]Ironwood stopped development of the candidate formerly designated IW-9179.
- 2012
Linaclotide is approved
[1]Linaclotide received approval in the United States and Europe for constipation-related gastrointestinal conditions.
- 2010
Initial public offering and industrial divestiture
[1]Ironwood held its IPO and later sold its interests in Microbia to DSM.
- 2008
Microbia drug business becomes Ironwood Pharmaceuticals
[1]The pharmaceutical company changed its name to Ironwood Pharmaceuticals, while the industrial business retained the Microbia identity.
- 2006
Industrial and pharmaceutical operations are separated
[1]Microbia divided its industrial biotechnology and drug-discovery activities into separate businesses. Tate & Lyle invested in the industrial spinout.
- 2004
Linaclotide advances toward clinical testing
[1]Microbia had raised $99 million and was preparing a Phase I trial for linaclotide.
- 2002
Drug-discovery leadership is expanded
[1]John Talley joined to lead antifungal drug discovery, alongside other experienced pharmaceutical and biotechnology leaders.
- 1998
Microbia is founded
[1]Postdoctoral researchers associated with the Whitehead Institute established Microbia to commercialize fungal fermentation technologies and pursue pharmaceutical discovery.
Products and positioning
A specialized gastrointestinal pharmaceutical company built around linaclotide and a focused pipeline of prescription medicines.
Prescription gastrointestinal medicine · 2012
Linzess
Linzess is the United States and Mexico brand name for linaclotide, Ironwood's principal commercial medicine. It is used for irritable bowel syndrome with constipation and chronic idiopathic constipation. The medicine is based on a peptide derived from an Escherichia coli enterotoxin and works through the intestinal guanylate cyclase-C pathway. Ironwood commercialized the product with partners in important markets.
Prescription gastrointestinal medicine · 2012
Constella
Constella is the brand name used for linaclotide in many markets outside the United States and Mexico. It addresses constipation-related gastrointestinal disorders, including irritable bowel syndrome with constipation and chronic idiopathic constipation. The international brand forms part of Ironwood's partnered commercialization model for linaclotide.
Clinical-stage gastrointestinal drug candidate
Recanaclotide
Recanaclotide, previously designated IW-9179, was an Ironwood gastrointestinal development program. The company discontinued its development in 2016, and it is not an active commercial offering.
Anxiolytic drug candidate
Soclenicant
Soclenicant, also known as BNC-210 and IW-2143, was a licensed anxiolytic program on which Ironwood conducted research and development. Ironwood later abandoned the program.
Brand decisions
2016
Discontinue recanaclotide developmentStrategyBackground
Ironwood reviewed its development portfolio after advancing multiple gastrointestinal candidates.
Action taken
The company abandoned the IW-9179, or recanaclotide, program.
Aftermath
The decision narrowed Ironwood's development portfolio around programs with stronger strategic priority.
2010
Divest the industrial biotechnology interestM&ABackground
Ironwood was concentrating on pharmaceutical development after separating its industrial activities.
Action taken
The company sold its interests in Microbia to DSM.
Aftermath
Ironwood completed its withdrawal from the industrial biotechnology business and became a focused pharmaceutical company.
Transaction value. (2010)
2008
Rename the pharmaceutical business Ironwood PharmaceuticalsStrategyBackground
After the 2006 separation, the drug-development company needed a distinct identity from the industrial biotechnology business.
Action taken
Microbia changed its name to Ironwood Pharmaceuticals, while the industrial business adopted the shorter Microbia name.
Aftermath
The Ironwood identity became associated with pharmaceutical research and the later commercialization of linaclotide.
2006
Separate industrial biotechnology from drug discoveryStrategyBackground
Microbia was managing industrial fermentation activities, antifungal research, and the expensive process of clinical drug development within one organization.
Action taken
The company split its operations into an industrial business, Microbia Precision Engineering, and a drug-discovery business that retained the Microbia name.
Aftermath
The separation enabled the pharmaceutical business to concentrate on drug development, while the industrial operation received outside investment from Tate & Lyle.
Tate & Lyle investment. $7 million (2006)
Recent events
Sources2 sources
Cite this profile: Cite the canonical profile. /brand-wiki/ironwood-pharmaceuticals · Editorial policy · How profiles are compiled